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Objective: Chymase is one of the inflammatory mediators and is released from mast
cells, which are closely associated with adhesion formation. Chymase also activates
transforming growth factor 1, which promotes tissue fibrosis. However, the role of
chymase in cardiac adhesion formation has not yet been elucidated. We have
assessed whether a specific chymase inhibitor, Suc-Val-Pro-Phep (OPh)2, prevents
postoperative cardiac adhesions in hamsters.
Methods: In 66 hamsters the epicardium was abraded, and then either chymase
inhibitor or placebo was injected into the left thoracic cavity, leaving the pericar-
dium open. Cardiac chymase activity, the level of transforming growth factor 1 in
the pleural fluid, and the density of epicardial mast cells were measured 3 days
postoperatively. The degree of adhesion formation was evaluated macroscopically
and histologically 2 weeks postoperatively by using a grading score ranging from 0
(no adhesions) to 4 (severe adhesions).
Results: The cardiac chymase activity and level of transforming growth factor 1
were lower in the chymase inhibitor–treated group compared with in the placebo-
treated group (45.8  18.7 vs 79.7  13.7 U/mg protein [P  .025] and 15.6 
6.5 vs 33.2  9.8 g/mL [P  .01], respectively). The density of mast cells was
higher in the placebo-treated group, and there was suppression to 60% of this value
in the chymase inhibitor–treated group. The adhesion scores were lower in the
chymase inhibitor–treated group compared with in the placebo-treated group (1.3
1.3 vs 3.0  1.1, P  .01).
Conclusion: Use of a chymase inhibitor suppresses not only cardiac chymase
activity but also the level of transforming growth factor 1, and this results in a
reduction in postoperative cardiac adhesion.
When surgical reintervention is needed, the presence of exist-ing postoperative adhesions remains a challenge, particu-larly in the field of cardiac surgery, in which the presence ofcardiac adhesions increases the postoperative and reopera-tive surgical hazards.1-3 Although numerous materials andpharmacologic agents have been experimentally assessed in
an effort to reduce the formation of adhesions, an ideal method has not yet been
found.
The mechanism of adhesion formation is not fully understood, although mast
cells, a type of inflammatory cell, are known to be closely associated with adhesion
formation.4-7 The number of mast cells increases in the initial inflammatory stage,
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and inhibition of the activation and accumulation of mast
cells with a mast cell stabilizer reduces intraperitoneal ad-
hesion formation in a rat model.4 In addition, in mast
cell–deficient mice intraperitoneal adhesion formation is
less severe than in normal control mice.5 Mast cells release
a large number of inflammatory mediators during adhesion
formation, including histamine, serotonin, chemotactic fac-
tors, cytokines, and serine proteases.6,7 However, it is not
clear which factor plays the major role.
Chymase is a chymotrypsin-like serine protease that is
present in the secretory granules of mast cells. Recently, it
has been found that chymase-containing serosal mast cells
in rats express, secrete, and activate transforming growth
factor 1 (TGF-1) by means of a secretory mechanism in
which chymase is coreleased as the TGF-1 activating
enzyme.8 TGF-1 is known to be closely associated with
adhesion formation, both in vitro9 and in vivo.10,11 There-
fore is seems likely that chymase plays a crucial role in
adhesion formation and that the use of a chymase inhibitor
could also inhibit the activation of TGF-1, with a resulting
reduction in postoperative cardiac adhesion formation.
In the present study we have investigated whether a
specific chymase inhibitor, Suc-Val-Pro-Phep (OPh)2, can
prevent postoperative cardiac adhesions in a hamster model.
Materials and Methods
Sixty-six mature male Syrian hamsters were used in the study.
They were all 15 weeks of age and weighed between 140 and
200 g. The study protocol had been approved by the Kyoto
University Ethics Committee for Animal Research. All animals
received humane care in compliance with the guidelines in the
“Principles of Laboratory Animal Care” formulated by the Na-
tional Society for Medical Research and the “Guide for the Care
and Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources, National Research Council, and
published by the National Academy Press (revised 1996).
Surgical Technique
After endotracheal intubation, hamsters underwent general anes-
thesia with 1% to 2% isoflurane by using a volume-cycled venti-
lator for small animals (Rodent Ventilator, Harvard Apparatus
683). The chest was opened through a left thoracotomy, taking
care to avoid injury to the underlying left lung. After pericardiot-
omy, the left side of the epicardium was abraded 100 times with
gauze, and then a single 7-0 polypropylene suture (Prolene, Ethi-
con Inc) was placed in the epicardium. During the procedure, the
operator was careful not to tear the fragile ventricular wall or
injure the left anterior descending coronary artery. In the chymase
inhibitor–treated group (n  33), 1 mL of 10 mol/L Suc-Val-
Pro-Phep (OPh)2 in normal saline was injected into the thoracic
cavity. In a similar manner 1 mL of normal saline was introduced
into the thoracic cavity in the placebo-treated group (n  33). The
pericardium was left open, and the chest was closed in 2 layers
with 4-0 polypropylene sutures (Prolene, Ethicon Inc).
Measurement of Cardiac Chymase Activity
In 10 hamsters, 5 from the placebo-treated group and 5 from the
chymase inhibitor–treated group, the whole heart was excised
during general anesthesia 5 minutes after the end of the operation.
In another 12 hamsters, 6 from each group, the hearts were excised
3 days postoperatively. These hearts were subject to rapid freezing
and were then stored at 80°C until use.
A tissue preparation method for the measurement of chymase
activity has been described previously.12 The heart was minced
and homogenized in 10 volumes (wt/vol) of 20 mmol/L Na-
phosphate buffer (pH 7.4). The homogenate was then centrifuged
at 10,000 rpm for 30 minutes, and the supernatant was discarded.
This procedure was repeated twice. The pellets were then resus-
pended and homogenized in 5 volumes (wt/vol) of 10 mmol/L
Na-phosphate buffer (pH 7.4) containing 2 mol/L KCl and 0.1%
Nonidet P-40. The homogenate was stored overnight at 4°C and
then centrifuged at 10,000 rpm for 30 minutes. Chymase activity
was measured, as described previously,13 in the resultant superna-
tant, which was used as the tissue extract.
Aliquots (20 L) of the tissue extract were incubated for 10
minutes at 37°C with 4 mmol/L angiotensin I in a 150 mmol/L
borax-borate buffer containing 5 mmol/L ethylenediamine tet-
raacetic acid, 8 mmol/L dipyridyl, and 0.77 mmol/L diisopropyl
phosphorofluoridate at pH 8.5 (resulting in a final incubation
volume of 0.1 mL). The reaction was terminated by the addition of
0.15 mL of 15% trichloroacetic acid. The samples were then
centrifuged at 10,000 rpm for 10 minutes. To perform a fluoro-
metric quantification of the angiotensin II metabolite His-Leu,
10% o-phthaldialdehyde (dissolved in neat methanol) was added to
the supernatant under alkaline conditions, and then 6N HCl was
added to stabilize the fluorescence for measurement at 340 nm of
excitation and 455 nm of emission. A blank fluorometric assay was
carried out after the addition of 0.5 mmol/L chymostatin (dimeth-
ylformamide solution). The protein concentration was measured
with a bicinchoninic acid protein assay reagent (Pierce Chemical),
with bovine serum albumin as the standard.
Measurement of TGF-1 Level
In 10 hamsters (5 from each group) TGF-1 was measured in an
intrapleural wash sample that had been collected at 2 time points:
after pericardiotomy but before adhesion creation and 3 days
postoperatively. One milliliter of normal saline was trickled into
the left thoracic cavity, and then this intrapleural wash sample was
collected and frozen. The level of TGF-1 was quantified by using
a TGF-1–specific enzyme-linked immunosorbent assay (R&D
Systems).
Assessment of Adhesions
In 22 hamsters (11 from each group) the degree of adhesion
formation was assessed 2 weeks postoperatively. During general
anesthesia, the chest was opened through a longitudinal right
anterior thoracotomy, and the degree of adhesion between the heart
and the chest wall was scored. The scores were graded blindly
according to the modified classification of Hulka and colleagues14:
no adhesions, score 0; mild adhesions, score 1; localized moderate
adhesions, score 2; moderate and extensive adhesions, score 3; and
severe adhesions that were impossible to separate, score 4. The
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presence of adhesion formation between the heart and the left lung
was also assessed.
Histologic Study
A histologic study was performed at 2 time points. In 12 hamsters
(6 from each group) the whole heart was excised 3 days postop-
eratively before the development of adhesions, and the degree of
mast cell accumulation was assessed. Mast cells around the epi-
cardium were counted by a blinded observer using 3 horizontal
cross-sections per specimen, one each from the apex, the midpor-
tion, and the base of the heart. In 22 hamsters (11 from each group)
the entire heart with the adherent chest wall was excised 2 weeks
postoperatively.
All the specimens were fixed in Carnoy solution, embedded in
paraffin, and cut into 3-m-thick sections. The cross-sections were
stained with hematoxylin and eosin and with toluidine blue to
demonstrate the mast cells.
Statistical Analysis
The statistical analysis was carried out with StatView software
version 5.0. Data are expressed as the mean 1 SD. A comparison
in adhesion score, chymase activity, and the density of mast cells
was performed by using the Wilcoxon test. The level of TGF-1
was evaluated by using the Wilcoxon test in a comparison between
the groups and by using the Wilcoxon signed-rank test in a
comparison between 2 time points in each group. Multiplicity of
analysis was adjusted by using the Bonferroni method. The relative
presence of adhesions between the heart and the lung was evalu-
ated with the 2 test.
Results
Preoperatively, there was no difference in body weight
between the 2 groups. There were no wound complications
in any of the hamsters up to 2 weeks postoperatively.
Cardiac Chymase Activity
The samples that were obtained 5 minutes postoperatively
showed no significant difference in cardiac chymase activity
between the 2 groups (34.2  20.8 U/mg protein in the
chymase inhibitor–treated group and 48.2  11.1 U/mg
protein in the placebo-treated group). However, by the third
postoperative day, the cardiac chymase activity in the placebo-
treated group (79.7  13.7 U/mg protein) was significantly
higher than that found in the chymase inhibitor–treated group
(45.8  18.7 U/mg protein; P  .025; Figure 1, left).
TGF-1 Level
Samples obtained at the time of the operation showed no
significant difference in the level of TGF-1 in the 2 groups
(11.7  3.8 g/mL in the chymase inhibitor–treated group
and 10.8  3.6 g/mL in the placebo-treated group). How-
ever, 3 days postoperatively, the level of TGF-1 in the
samples from the placebo-treated group (33.2 9.8 g/mL)
was significantly higher than that in the chymase inhibitor–
treated group (15.6  6.5 g/mL; P  .01; Figure 1, right).
Assessment of Adhesions
Representative photographs of the areas of adhesion are
shown in Figure 2. In the placebo-treated group 64% of
hamsters had a score of 3 or 4 compared with the chymase
inhibitor–treated group in which 64% had a score of 0 or 1
(Table 1). The average adhesion formation score in the
chymase inhibitor–treated group (1.3  1.3) was signifi-
cantly lower than that found in the placebo-treated group
(3.0  1.1; P  .01). Adhesions between the heart and the
adjacent left lung were found more frequently in the place-
bo-treated hamsters (91%) compared with in the chymase
inhibitor–treated hamsters (27%, Table 1). This difference
was also significant (P  .01).
Histologic Study
Figure 3 shows a representative photograph of the micro-
scopic findings of mast cells on the epicardium in a placebo-
Figure 1. Left, The cardiac chymase activity in the chymase inhibitor–treated and the placebo-treated group 5
minutes after the end of the operation and 3 days postoperatively. *P < .025. Right, The level of TGF-1 in the
pleural fluid in the chymase inhibitor–treated and the placebo-treated group perioperatively and 3 days postop-
eratively. **P < .01.
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treated hamster 3 days postoperatively. Mast cells, the pos-
itive cells that have stained with toluidine blue, are seen to
have accumulated on the epicardium with observable de-
granulation. In the placebo-treated group the density of mast
cells was greater than in the chymase inhibitor–treated
group, in which there were only 60% as many mast cells.
(Table 2). However, this difference did not reach statistical
significance.
Figure 4 shows a typical adherent lesion between the
heart, the left lung, and the chest wall in a placebo-treated
hamster 2 weeks postoperatively. This lesion has been
stained with hematoxylin and eosin and with toluidine blue.
An accumulation of mast cells was also seen in this lesion.
Discussion
The effect of postoperative adhesions, both on the surgical
patient and on the risks during reoperation, has been well
recognized in both cardiac and general surgery. In cardiac
surgery adhesions between the sternum and the heart can
lead to catastrophic hemorrhage during resternotomy,1 and
can cause right ventricular dysfunction2 and decreased cor-
onary artery bypass graft patency.3
Figure 2. Representative photographs of adherent areas in the placebo-treated and the chymase inhibitor–treated
hamsters 2 weeks postoperatively.
TABLE 1. Macroscopic assessment of adhesion formation
2 weeks after the operation
Treatment
Scores
0 1 2 3 4
Placebo 0 1 3 2 5
Chymase inhibitor 4 3 2 1 1
Treatment
Adhesions between the heart
and the lung
Yes (n) No (n)
Placebo 10 1
Chymase inhibitor 3 8
Figure 3. A section from the heart excised 3 days postoperatively
and stained with toluidine blue. Arrows indicate the mast cells.
Mast cells with marked degranulation are seen to be accumu-
lating on the epicardium.
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Closure of the pericardium has been recommended,15 but
it is not possible to do this in all cases because pericardial
closure might compress the heart, the bypass grafts, the
extracardiac conduits, or other areas. In an attempt to pre-
vent cardiac adhesions, there has been a recent trend toward
the use of foreign physical barriers rather than pharmaco-
logic agents. These barrier methods have included such
techniques as an expanded polytetrafluoroethylene nonab-
sorbable sheet or a hyaluronic acid bioabsorbable mem-
brane. However, although the expanded polytetrafluoroeth-
ylene sheet might obviate cardiac injury at resternotomy, it
can form undesirable adhesions with the heart16 or the
bypass graft. The clinical indication for the hyaluronic acid
bioabsorbable membrane is currently restricted to abdomi-
nal operations. The ideal method to prevent cardiac adhe-
sion has not yet been found.
In this study we have demonstrated for the first time that
a specific chymase inhibitor, Suc-Val-Pro-Phep (OPh)2, at-
tenuates postoperative cardiac adhesion formation in vivo.
When the chymase inhibitor was administered locally
around the surgical lesion at the time of the operation,
cardiac chymase activity, TGF-1 level, and the density of
mast cells on the epicardium were all suppressed 3 days
postoperatively (early phase). In addition, the adhesion for-
mation scores were reduced 2 weeks postoperatively (late
phase). Our results suggest that chymase produced from
mast cells plays an important role in adhesion formation,
although longer postoperative observation might be neces-
sary in terms of clinical simulation.
In this study a single dose of a chymase inhibitor was
effective in reducing postoperative cardiac adhesion forma-
tion. Oleksyszyn and Powers17 were the first to characterize
the specific chymase inhibitor Suc-Val-Pro-Phep (OPh)2,
which was used in this study. The half-degradation time of
the chymase inhibitor in human plasma is about 20 hours.
Chymase exists in mast cell granules and is rapidly released
through the process of degranulation when there is a strong
stimulus, such as surgical intervention or injury. It then
binds to the extracellular matrix and continues to function
for several weeks.18 The chymase inhibitor is considered to
bind irreversibly to chymase and then to reduce chymase
function for several weeks.19 These findings suggest that an
initial dose of a chymase inhibitor might be effective for
several weeks. Indeed, we have previously found that chy-
mase activity is significantly suppressed in vascular tissues
for up to 3 months, even when a single dose of chymase
inhibitor is administered during the operation at the same
dose that was used in the present study.12,20 Therefore it is
likely that cardiac chymase activity is inhibited by periop-
erative treatment with chymase inhibitor even 2 weeks
postoperatively, as in the present study. No side effects of
the chymase inhibitor were detected. It was administered
locally and once during the operation, which might have
minimized any side effects.
The present study is the first to demonstrate that the level
of TGF-1 at the surgical site increases in parallel with the
level of cardiac chymase activity after cardiac operations
and that this increase is suppressed by perioperative treat-
ment with a chymase inhibitor.
TGF-1 is considered to be related to adhesion forma-
tion8-11,21 because it can induce intraperitoneal adhesion
formation.10 In addition, antibodies to TGF-1 inhibit ab-
dominal adhesions in the rat.11 TGF- enhances the forma-
tion of connective tissue and promotes tissue fibrosis and
inflammatory cell infiltration.21 Recently, it has been found
that chymase-containing rat serosal mast cells are capable of
the expression, secretion, and activation of TGF-1 by
means of a secretory mechanism in which the largely latent
TGF-1 and the activating enzyme (chymase) are core-
leased.8 Mature TGF-1 is stored in a largely latent form in
the cytoplasmic secretory granules of the mast cells. Mast
cell stimulation and degranulation leads to immediate se-
cretion and activation of the largely latent TGF-1.8 In
combination with these previous findings, our results sug-
gest that the prevention of cardiac adhesion formation by
chymase inhibitor might be dependent on suppression of
TGF-1 activation by chymase.
In the present study the density of mast cells on the
epicardium 3 days postoperatively (early phase) was re-
duced in the chymase inhibitor–treated group compared
with in the placebo-treated group (Table 2). Chymase has
been reported to activate stem cell factor, a major cytokine
regulator of mast cell growth and function. Stem cell factor
also induces the accumulation of mast cells.22 Chymase is
also known to induce the accumulation of other inflamma-
tory cells, such as neutrophils and eosinophils, both of
which are related to tissue remodeling. Therefore it is pos-
sible that a chymase inhibitor could suppress the additional
accumulation of these inflammatory cells, which is induced
by chymase, and that this would result in an attenuation of
postoperative cardiac adhesions.
Chymase has been identified primarily as the major an-
giotensin II–forming enzyme in the human heart.23 It is
known that hamster, monkey, and dog chymase all have the
same chymase-dependent angiotensin II–generating system
as in human subjects, although rat chymase uses a different
TABLE 2. Density of mast cells around the epicardium 3
days postoperatively
Treatment
No. of mast cells
Base Midportion Apex Average
Placebo 21 12 23 13 16 8 20 10
Chymase inhibitor 16 9 13 5 10 8 12 6
Average is defined as the total number of mast cells: (base  midportion
 apex)/3. Data are expressed as the mean  1 SD.
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system.24 In addition, hamster chymase has shown a quite
similar character to human chymase from a viewpoint of the
tolerance against serine protease inhibitors.25 For these rea-
sons, hamsters were chosen as the model in this study.
Limitations
Despite perioperative treatment with a chymase inhibitor, in
2 (18%) of 11 of the treated hamsters, moderate-to-severe
adhesions were found. The most appropriate dose or deliv-
ery method needs to be verified, and in addition, the signal
transduction between chymase and TGF-1 needs to be
clarified.
Conclusion
We have demonstrated that a specific chymase inhibitor,
Suc-Val-Pro-Phep (OPh)2, reduces postoperative cardiac ad-
hesion formation in a hamster model. Although further
study is still necessary, this might be a useful technique for
the attenuation of postoperative adhesions.
We thank Dr Oleksyszyn (Wroclaw Technical University, Po-
land) for the gift of Suc-Val-Pro-Phep (OPh)2.
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